Pulmatrix, Inc., formerly Ruthigen, Inc., is a clinical stage biotechnology company. The Company is engaged in developing inhaled therapies to address pulmonary disease using its iSPERSE (inhaled small particles easily respirable and emitted), a dry powder technology. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. Its pipeline of products includes PUR0200, a once daily inhaled bronchodilator for chronic obstructive pulmonary disease, PUR1500, for the treatment of idiopathic pulmonary fibrosis (IPF), and PUR1900, an inhaled anti-infective for the treatment of cystic fibrosis. In addition, the Company is engaged in developing inhaled therapies for pulmonary diseases that affect large patient populations, such as chronic obstructive pulmonary disease (COPD) and asthma.